Bronchoscopic Lung-Biopsy Techniques Have Fewer Complications
New multidisciplinary guidelines bronchoscopic lung biopsy techniques offer tissue sampling adequacy comparable to other testing methods.
Category: Lung Cancer
Lung Cancer
Latest
Lung Cancer
Latest
Biofidelity Launches Test Offering Rapid Genomic Profiling for NSCLC Patients
Biofidelity’s test delivers comprehensive genomic profiling for NSCLC patients from tissue or liquid biopsy samples within two days.
Lung Cancer
Latest
NeoGenomics’ Solid Tumor Test Gets New York State Approval
NeoGenomics received conditional approval from the New York State Department of Health for its Neo Comprehensive Solid Tumor and NeoTYPE DNA & RNA Lung assays.
New Test Influences First-Line Therapy Decisions for Metastatic NSCLC Patients
A new study from OncoHost reveals that its PROphetNSCLC test impacts oncologists’ first-line treatment decisions for metastatic NSCLC.
Read More
Development of Breath Test for Lung Disease is Underway
Researchers have developed a potential exhaled-breath test for lung diseases by successfully collecting lung biomarkers from human breath.
Read More
AI Blood Test Reliably Identifies Lung Cancer
Researchers have developed an AI-powered liquid biopsy to identify lung cancer earlier through DNA fragment patterns in blood.
Read More
DELFI Diagnostics’ Blood Test Validated for Early Lung Cancer Detection
DELFI’s blood-based Lung test has been clinically validated to enhance early detection of lung cancer, demonstrating high sensitivity.
Read More
PROphet Platform’s Predictive Ability to be Demonstrated
OncoHost will highlight the PROphet platform’s capability to predict benefits from therapies across various cancers.
Read More
DELFI Collaborates with Hospital System to Improve Lung Cancer Screening
OSF HealthCare will use DELFI’s FirstLook Lung blood test to enhance lung cancer screening rates and early detection efforts.
Read More
CAP Publishes Guideline for PD-L1 Testing of Lung Cancer Patients
CAP developed recommendations for testing immunotherapy biomarkers, such as PD-L1 and TM), in patients with NSCLC.
Read More
Nucleix’s New Assay May Differentiate Small Cell Lung Cancer Subtypes
Nucleix will present data that demonstrates the potential of a PCR assay to accurately differentiate between small cell lung cancer subtypes.Â
Read More
Study Demonstrates Clinical Validity of OncoHost’s NSCLC Test
The test guides first-line treatment selection by identifying individuals with the highest likelihood of benefit from PD-1/PD-L1 inhibitors
Read More
Noninvasive Testing Key to Id’ing Lung Cancer
New noninvasive diagnostic solutions for lung cancer being developed function as a complement to LDCT imaging.
Read More
New Epigenomic Technology Platform Predicts Immunotherapy Response in NSCLC Patients
The epigenomic technology platform predicts and monitors immunotherapy responses for patients with non-small cell lung cancer (NSCLC).
Read More
New ChromaCode Collaboration to Improve NSCLC Biomarker Testing Access
ChromaCode will collaborate with Tennessee Oncology to test the performance of ChromaCode’s HDPCR NSCLC biomarker assay.Â
Read More
New Sensor Technology May Enable Early Lung Cancer Detection
The diagnostic, which requires only a simple urine test to read the results, could make lung cancer screening more accessible worldwide.
Read More
Freenome Initiates Clinical Study of Blood Test for Early Lung Cancer Screening
Freenome’s PROACT LUNG study is intended to validate the clinical performance of its blood test for lung cancer screening.Â
Read More
DELFI Diagnostics Supports Legislation for CMS to Review New Lung Cancer Liquid Biopsies
DELFI Diagnostics is supporting the recently introduced Lung Cancer Screening and Prevention Act (H.R. 6693).
Read More